Skip to main content
رجوع
Watch Compare

Akari Therapeutics Plc

جودة البيانات: 83%
AKTX
Nasdaq Manufacturing Chemicals
KWD 3.92
▲ KWD 0.04 (1.03%)
القيمة السوقية: 4.49 M
السعر
KWD 3.92
القيمة السوقية
4.49 M
نطاق اليوم
KWD 3.77 — KWD 3.99
نطاق 52 أسبوعًا
KWD 3.25 — KWD 63.20
حجم التداول
8,389
فتح KWD 3.83
متوسط 50 يوم / 200 يوم
KWD 8.56
54.20% below
متوسط 50 يوم / 200 يوم
KWD 24.65
84.10% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -10.57 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-71.64%
أقل من متوسط القطاع (-53.41%)
ROIC-42.93%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio0.19
Interest Coverage-172.75

التقييم

PE (TTM)
-0.26
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.20
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.3 -1.5
P/B 0.2 1.6
ROE % -71.6 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -17.30 M
ROE -71.64% ROA -35.93%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10.57 M
ROIC -42.93% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.19
Interest Coverage -172.75 Asset Turnover N/A
Working Capital -12.62 M Tangible Book Value 14.26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.26 Forward P/E N/A
P/B Ratio 0.20 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -235.54%
Market Cap 4.49 M Enterprise Value 4.49 M
Per Share
EPS (Diluted TTM) 0.00 Revenue / Share N/A
FCF / Share -9.23 OCF / Share -9.23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 61.09%
SBC-Adj. FCF -13.24 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -17.30 M -19.79 M -10.01 M -17.75 M -17.42 M
EPS (Diluted) 0.00 0.00 0.00 0.00 0.00
Gross Profit — — — — —
Operating Income -17.28 M -21.64 M -16.81 M -23.09 M -17.21 M
EBITDA — — — — —
R&D Expenses 2.82 M 6.98 M 5.45 M 9.56 M 9.13 M
SG&A Expenses 9.28 M 9.66 M 11.36 M 13.53 M 8.08 M
D&A 14,000.0 14,000.0 4,000.0 3,708.0 4,126.0
Interest Expense 100,000.0 244,000.0 — — —
Income Tax -1.00 M 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 47.89 M 50.56 M 4.36 M 13.83 M 11.65 M
Total Liabilities 19.56 M 28.33 M 4.58 M 12.04 M 6.09 M
Shareholders' Equity 28.33 M 22.23 M -229,000.0 1.79 M 5.55 M
Total Debt — — — — —
Cash & Equivalents 0.0 2.60 M 3.85 M 13.25 M 9.36 M
Current Assets 5.46 M 2.95 M 4.34 M 13.81 M 11.63 M
Current Liabilities 12.35 M 19.91 M — — —